PARAGON-II is a Phase II, non-randomised, open-label, basket study aiming to evaluate the activity and tolerability of combination aromatase inhibitor with a CDK4/6 inhibitor or PIK3CA inhibitor in post-menopausal patients with advanced (recurrent/metastatic) hormone-receptor positive (HR+) gynaecological cancers.
Medical Research Future Fund 2019 RCRDUN, Novartis
Patients with histologically proven recurrent/metastatic, HR+, cancers of the ovaries, fallopian tubes, or peritoneum (including high-grade and low-grade serous cancers), granulosa cell ovarian cancers and endometrial cancer (including epithelial cancers and sarcomas).
Australia and New Zealand
Australian Lead Group:
Australia New Zealand Gynaecological Oncology Group (ANZGOG)